US3014844A - Self-propelling powder dispensing compositions - Google Patents

Self-propelling powder dispensing compositions Download PDF

Info

Publication number
US3014844A
US3014844A US706908A US70690858A US3014844A US 3014844 A US3014844 A US 3014844A US 706908 A US706908 A US 706908A US 70690858 A US70690858 A US 70690858A US 3014844 A US3014844 A US 3014844A
Authority
US
United States
Prior art keywords
powder
propellant
freon
crystalline
column
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US706908A
Other languages
English (en)
Inventor
Charles G Thiel
Ronald D Law
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Riker Laboratories Inc
Original Assignee
Riker Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BE556587D priority Critical patent/BE556587A/xx
Application filed by Riker Laboratories Inc filed Critical Riker Laboratories Inc
Priority to US706908A priority patent/US3014844A/en
Priority to GB2644/58A priority patent/GB837465A/en
Priority to DER22567A priority patent/DE1178975B/de
Priority to FR756970A priority patent/FR1228811A/fr
Priority to NL224547D priority patent/NL224547A/xx
Priority to NL224547A priority patent/NL106832C/xx
Application granted granted Critical
Publication of US3014844A publication Critical patent/US3014844A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A01N25/06—Aerosols
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/30—Materials not provided for elsewhere for aerosols
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0043—For use with aerosol devices

Definitions

  • This invention relates to self-propelling. power-dispensing compositions capable of dispensing powdered material in aerosol form and to a means for dispensing a dry powder in aerosol form having controlled particle size.
  • compositions of the invention comprise a finely-divided active solid material or powder suspended in a liquified propellant, in which the solid material is substantially insoluble, and a non-ionic surface-active agent which is liquid at room temperature (65 F.), or ambient temperatures.
  • he finely divided powder may constitute from about 0.01 to 20% by weight of the total composition. Desirably it shall constitute from about 0.05% to 10%, and referably 0.1 to 3%, by weight of the total composition.
  • the surface-active agent may constitute from about 0.1 to 20%, desirably between about 0.25 and 5%, and preferably, for medicinal purposes, between about 0.25 and 1%, by weight of the total composition, with the liquified propellant constituting the remainder of the composition.
  • the concentration of surfaceactive'agent is kept at a minimum as it may tend to solubilize the powder in the propellant, which is undesirable for reasons which will be explained below.
  • the particle-size of the powder should desirablybe uniform and not greater than microns diameter, since larger particles may tend to agglomerate, separate from the suspension and may clog thevalve or orifice. of the container.
  • the particle size should be less than 25- microns in diameter.
  • the. particlesize of the finely-divided solid powder should for physiological reasons be less than 25 microns and preferably less than 10 microns in diameter.
  • the size of the particles of powder should be substantially uniform. There is no lower limit of particle size except'that'which is imposed by the use to which the aerosol produced is to be put. Where the powder is a solid medicament, the lower limit of particle size is that which will be readily absorbed and retained on or in body tissues. When particles less than one micron in diameter are administered by inhalation they tend to be re-exhaled by the patient.
  • the finely-divided powder should be substantially insoluble in each of the liquified propellant, the surface-active agent and in a liquified propellant-surface-active mixture.
  • the powder is substantially soluble, crystal growth may occur and the particle size of the aerosolized powder when dispensed cannot be controlled.
  • compositions of the invention are intended to be used for dispensing powders in aerosol form by operating the valve of a pressuretight container charged with the compositions, it is desirable that the particle size of the suspended powder be regulated and agglomeration reduced. It is clear that if agglomeration of the powder takes place, it may tend to clog the narrow valve orifice and render the dispensing device inoperative, or it a metering valve is employed, it may be rendered inaccurate. This may lead to inaccurate dosages, which in the case of highly potent medicinals may lead to undesirable results. In addition to increasing 3 make the suspension unstable and of unsuitable appearance. In the case of powdered medicinals, adsorption in the body may be made ineffective. Consequently, it is desirable that the finely-divided powder be substantially insoluble in the other components of the compositions.
  • a finely-divided powder such as a medicament
  • a finely-divided powder tends to be somewhat soluble in the mixture of surfaceactive agent and liquified propellant
  • a less soluble form of the powder For example, instead of employing the base phenylephrine, its hydrochloride may .be employed.
  • different liquified propellants may be employed in which the powder is less solubie.
  • compositions of the invention Illustrative of the versatility of the compositions of the invention is the fact that the solid components may be amorphous or crystalline in nature. We prefer to use crystalline materials, as is indicated by the specific examples given below. Early efforts to produce self-propelling powder dispensing compositions showed that even to obtain compositions having only borderline properties, it was necessary to limit the solid materials employed to amorphous materials.
  • compositions of the present invention do not require the presence of a polar solvent, such as water.
  • a polar solvent such as water.
  • the compositions may be substantially anhydrous.
  • moisture control is important at all stages of processing.
  • Another means of controllingand reducing the moisture content of the composition is to introduce before closing the container in which the composition is packaged, small fragments of an anhydrous, nonreactive desiccant, such as silica gel or calcium sulfate. This reduces the moisture content of the liquid phase of the composition below that which causes agglomeration.
  • an anhydrous, nonreactive desiccant such as silica gel or calcium sulfate. This reduces the moisture content of the liquid phase of the composition below that which causes agglomeration.
  • desiccant is sutficien-t for a 10 ml. container charged with composition.
  • the solid active component to be aerosolized may be a: medicament, such as a vasoconstrictive amine or its acid-addition salts, a hormone, enzyme, alkaloid, steroid, analgesic, bronchodilator, antihistamine, antitussive, an-
  • medicament such as a vasoconstrictive amine or its acid-addition salts, a hormone, enzyme, alkaloid, steroid, analgesic, bronchodilator, antihistamine, antitussive, an-
  • medicaments which may be employed are: isoproterenol [alpha- (isopropylaminomethyl)protocatechuyl alcohol] hydro- .chloride or sulfate, phenylephrine, phenylpropanolamine,
  • glucagon adrnochrome, trypsin, epinephrine, ephedrine, narcotine, codeine, atropine, morphine, dihydromorphinone, ergotamine, scopolamine, methapyrilene, cyanocobalamin, and colchicine.
  • Others are antibiotics such as ncomycin, streptomycin, penicillin, procaine penicillin, tetracycline, chlorotetracycline and hydroxytetracycline;
  • the active solid component may also be a cosmetic substance such as talc, an antiperspirant such as aluminum chlorohydrate,
  • a lubricant such as graphite and other finely-divided materials; as well as other usefulsubstances.
  • the liquified propellant employed is one which is a gas at room temperature (65 F.) and atmospheric pressure (760 mm. of mercury), i.e., it shall have a boiling point below 65 F. at atmospheric pressure.
  • the liquified propellant should be non-toxic.
  • suitable liquitied propellants which may be employed are the lower alkanes containing up to five carbon atoms, such as butane and pentane, or a lower alkyl chloride, such as methyl, ethyl or propyl chlorides.
  • the most suitable liquified propellants are the fiuorinated aand fiuorochlorinated lower alkanes such as are sold under the trademark Freon. Mixtures of the above mentioned propellants may suitably be employed.
  • the fiuorinated or flLlOIOChiOI'b nated lower alkane shall contain not more than two carhon atoms and at least one fluorine atom.
  • Examples of these propellants are dichlorodifluoromethane (Freon l2), dichlorotetrafiuoroethane (Freon 1 l4) CClF .CC1F trichloromonofiuoromethane (Freon 11), dichloromonofluoromethane (Freon 2l) monochloroditluoromethane (Freon 22), trichlorotrifluoroethane (Freon 113), and monochlorotrifluorm methane (Freon l3).
  • Propellants with improved vapor pressure characteristics may be obtained by using certain mixures of these compounds, e.g., Freon 11" with Freon 12, or Freon 12" with Freon 114.”
  • the vapor pressure of the propellant employed shall itself be Between about 25 and 65 pounds per square inch gauge at 70 F., arid prefer bly between about 30 and 40 pounds per square inch gauge at that temperature.
  • a one-component propellant defined for use in the composition was found to give a composition with gauge pressures in the range of 55 to 65 pounds per square inch at 70 R, which are usable safely with metal containers.
  • the two-component propellants such as equal weight mixtures of "Freon 12 and Freon 11, were found to give gauge pressures in the range of 20 to 40 pounds per square inch at 70 R, which are usable safely with specially reinforced glass containers.
  • valves of simple construction may be used, and there is no need to provide special nozzles and expansion chambers, as is usually required when dispensing materials surface coating, which may even be a mono-molecular film or layer, on the finely-divided powder which prevents the particles from agglomerating either while dispersed in the propellant or when in the valve of the container.
  • the liquid, non-ionic, surface-active agent employed should have an hydrophile-lipophile balance (HLB) ratio of less than 10.
  • HLB ratio is an empirical number which provides a guide to the surface-active properties of a surface-active agent. The lower the HLB ratio, the more lipophilic is the agent, and conversely, the higher the HLB ratio, the more hydrophiiic is the agent.
  • the HLB ratio is well known and understood by the colloid chemist and its method of determination is described by W. C. Grifiin in the Journal of the Society of Cosmetic Chemists, vol. 1, No. 5, pages 311-326 (1949).
  • the surface-active agent employed should have an HLB ratio of about 1 to 5. It is possible to employ surface-active agents which themselves do not possess an HLB ratio within these ranges, providing they are used in conjunction with other surface-active agents which have an HLB ratio which will provide a mixture having an HLB ratio within the prescribed range.
  • Lubricants for the valve such as calcium stearate, which is without surfactant properties, were not found to be satisfactory, because they do not help to keep the powdered medicament uniformly dispersed in the pro pellant.
  • the surfaceactive agent should be non-irritating and non-toxic.
  • liquid non-ionic surfaceactive agents which may be employed in our compositions are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octoic, lauric, palmitic, stearic, linoleic, linolenic, eleostearic and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride such as, for example, ethylene glycol, glycerol, erythritol, arabitol, mannitol, sorbitol, the hexitol anhydrides derived from sorbitol (the sorbitan esters sold under the trademark Spans”) and the polyoxyethylene and polyoxypropylene derivatives of these esters.
  • an aliphatic polyhydric alcohol or its cyclic anhydride such as, for example, ethylene glycol, glycerol, erythritol, arabitol, manni
  • sorbitan e.g., those sold under the trademarks Arlacel C (Sorbitan sesquioleate), Span 80 (sorbitan monooleate) and Span 85 (sorbitan trioleate).
  • MYRJ 45 Polyoxyethylene Very good suspension, elumpy, stearate. sticks to container, breaks very rapidly, lubrieates valve.
  • Bi-i Polyoxyctliylenelauryl Very poor suspension, clumpy,
  • compositions of the invention employing certain finely-divided powders there is a tendency to form a layer of powder at the surface of the propellant in the container and that these layers tend to deposit or cake" powdered material on the container walls above the liquid level. This has been found to occur only with those powders which have a specific gravity less than that of the propellant.
  • the undesirable deposition or caking which results where the specific gravity of the finely divided powder is substantially less than that of the propellant can be overcome by lowering the specific gravity of the liquid phase, for example by using a propellant of lower specific gravity, such as butane, or by increasing the specific gravity of the solid active powder component, for example in the case of phenylephrine by using the bitartrate salt instead of hydrochloride.
  • a propellant of lower specific gravity such as butane
  • the specific gravity of the solid active powder component for example in the case of phenylephrine by using the bitartrate salt instead of hydrochloride.
  • auxiliary solid may be of any chemical type, provided that it is compatible with the other ingredients and insoluble in the propellant.
  • an inorganic compound such as sodium sulfate, calcium chloride or sodium chloride.
  • an organic material such as powdered lactose, sucrose, epinephrine bitartrate, neomycin sulfate, or graphite.
  • the auxiliary solid when used in medicinal and cosmetic preparations, should be non-toxic and nonirritant. In all cases it should be without deleterious effect on the properties of the dispensed product or on the user.
  • the particle size of the auxiliary solid should pp in this suitable for inhalation therapy.
  • PU is equal to or greater than pp (3) thus when q equals 11, equals zero. less than [312, the following exists:
  • compositions of the invention may-be used to apply measured amounts of aerosolized solid medicaments into body cavities such as the throat or nose. They also provide a means of producing aerosolized medicaments Inhalation therapy is prompt through the intimate contact with the blood through the alveolar membrance. It also enablm drugs to act directly on respiratory sites without engendering undesirable systemic effects as happens often When drugs are administered by other routes. With very volatile substances inhalation approaches intravenous therapy in rapidity of. action. It willoften avoid the necessity of parenteral injections.- Previously aerosols for this purpose have been prepared by nebulizing aqueous solutions,
  • a container equipped with a valve is filled with a propellant containing the finely-divided powder in suspension.
  • a container may first be charged with a weighed amount of dry powder which has been ground to a predetermined particle size, or in a slurry of powder in the cooled liquid propellant.
  • the powder and the surface-active agent may be triturated or homogenized first into a uniform paste, for instance, by a pestle and mortar. This paste is then dispersed in the cooled liquefied propellant. This procedure fosters uniform wetting of the powder particles.
  • a container may also be filled by introducing powder and propellant by the normal cold filling method, or a slurry of the powder in that component of the propellant which boils above room temperature may be placed in the container, the valve sealed in place, and the balance of the propellant may be introduced by pressure filling through the valve nozzle.
  • the powder On operating the valve, the powder will be dispensed in a stream of propellant, which will vaporize providing an aerosol of dry powder.
  • the preparation of the product care is desirably exercised to minimize the absorption of moisture where the powder is water-soluble. This may be accomplished by operat-' .ing in a dehumidified atmosphere using only dry materials and equipment.
  • Example 1 Percent Hydrocortisone acetate, crystalline (more than 90% by weight within the particle size range of l to 5 microns) 3.0 Span 85 (sorbitan trioleate) 1.0 Freon l1 (trichloromonofluoromethane) 30.0 Freon 114 (dichlorotetrafiuoroethane) 41.0 Freon 12 (dichlorodifiuoromethane) 25.0
  • Example 2 Gm. Trypsin, amorphous (more than 90% by weight within the particle size range of l to 10microns) 0.10
  • Example 3 Percent Pre dnisolone acetate, crystalline (more than 90% by weight within the particle size range of l to 5 microns) 0.5 Span 85 (sorbitan trioleate) 0.5 Propellant B 99.0
  • Prcpellant B consists of:
  • Freon 11 (trichloromoncfiuoromethane) 10.0 Freon 114 (dichlorotetrafluorcethane) 50.4 Freon 12" (dichlorctetrafluoroethanc) 31.6 Butane a; 8.0
  • Example 4 ACTH (adrenocorticotropin) (amorphous) (l USP units/mg.) (more than 90% by weight within the particle size range, of 1 to 20 micron's) N 1.00
  • Insulin amorphous (more than 90% by weight I within the particle size range of 1 to 5 microns) 0.25 Span 85 (sorbitan trioleate) 0.25 Freon W (as defined in Example 2) 99.50
  • Example 7 Epinephrine, crystalline (free base) (more than 90% by weight within the particle size range of 1 to 5 microns 0.28 Span 85 (sorbitan. trioleate) 0.25 Freon 11 (trichlorornonofluorometha-ne) 5.00
  • Example 8 Epinephrine bitartrate, crystalline (more than 90% by weight withinthe particle size range of 1 to 5 microns) 0.50 Span 85(sorbitan trioleate) 0.50 Freon 11"'(trichloromonofluoromethane) 49.50 Freon '12 (dichlorodifluoromethane) .l- 49.50
  • Example 9 Isopropylarterenol hydrochloride, crystalline (more than 90% by weight within the particle size range of l to 5 microns) 0.25 Span (sorbitan trioleate) 0.25 Freonll (trichlorornonofluoromethane) 49.75 Freon l2 (dichlorodifiuorcmethane) 49.75
  • Example 10 Phenylephrine hydrochloride, crystal-line (more than by weight within the particle size range of l to 25 microns) 0.25 Ncomycin sulfate 0.11 Hydrowrtisone 0.04 Span S5" (sorbitan trioleate) 0.25 Freon ll (trichloromonofiuoromethane) 49.675 Freon l2 (dichlorodifluorornethane) 49.675
  • Example 12 Hydrocortisene acetate, crystalline (more than 90% by weight within the particle size range 'of l to 5 microns) 0.50
  • Surfactant 6-1087 polyoxyethylene sorbitol hexaoleate
  • a, 0.50 Propcllant C 99.00
  • Example 13 Percent Hydrocortisone acetate, crystalline (more than 90% by weight within the particle size range of 1 to 5 microns) 0.50 Arlacel C (sorbitan sesquioleate) 0.50 Propellant C (as defined by Example 12) 99.00
  • Example 14 Hydrocortisone acetate, crystalline (more than 90% by weight within the particle size range of 1 to 5 microns) 0.50 Span 80 (sorbitan monoleate) 0.50 Propellan-t- C (as defined-by Example 12) 99.00
  • Example 15 Hydrocortisone acetate, crystalline (more than 90% by weight within the particle size range of 1 to 5 microns) 0.50 Span S5 (sorbitan trioleate) 0.50 Propellant C-(as defined by Example 12) 99.00
  • Narcotine crystalline (more than 90% by weight within the particle size range of 1 to microns) 10.00 Span 85 (sorbitan trioleate) 1.00 Freon W (as defined by Example 2) 89.00
  • Example 17 "Dilaudid, crystalline (dihydrornorphinone hydrochloride) (more than 90% by weight within the particle size range of 1 to 5 microns) 0.5 Span 85 (sorbitan trioleate) 1.0 Freon 11 (trichloromonofiuoromethane) 30.0 Freon W" (as defined by Example 2) 68.5
  • This composition is useful for polishing optical components.
  • Example 19 Percent Hydrocortisone acetate, crystalline (more than 90% 'by weight within the particle size range of 1 to 5 microns) 0.5 Olive oil 0.5 Freon 11 30.0 Freon W (as defined by Example 2) 69.0
  • Example 20 Phenylephrine hydrochloride (crystalline), micronized 0.25 Phenylpropanolamine hydrochloride (crystalline), micronized 0.50 'Neomycin sulfate (crystalline), micronized 0.10 Hydrocortisone (crystalline), micronized 0.04 Sodium sulfate (anhydrous), micronizcd 0.35 Span 85" (sorbitan trioleate) 0.80 Prd'pellant S 97.96
  • Propellant S consists of:
  • Example 25 Phcnylephrine hydrochloride (crystalline), micronized 1.0 Neomycin sulfate (crystalline), micronized 3.0 Span 85 (sorbitan trioleate) 1.0 Propellant S (as defined by Example 20) 95.0
  • Propellant S-2 consists of:
  • Neomycin sulfate (crystalline), micronized 0.08
  • Propellant X consists of:
  • Freon 12 (dichlorodifluoromethane) 30 Freon 11 (trichloromonofiuoromethane) 30 Freon 114 (dichlorotetrafluoroethane) 40
  • Phenylephn'ne hydrochloride (c ystalline), mi-
  • Neomycin sulfate crystalline
  • micronized 0.08 Thenylpy'ramine hydrochloride crystalline
  • Example 31 Isoproterenol sulfate, crystalline, micronized 0.15 Span 85 (sorbitan trioleate) 0.50 Freon 113 (trichlorotrifiuoroethane) 0.95 Freon 11 (trichloromonofiuoromethane) 24.60 Freon 114 (dichlorotetrafluoroethane) 24.60 Freon 12 (dichlorodifiuoromethane) 49.20
  • Example 34 Crystalline glucagon, micronized 0.156 "Span 85- 0.468 Propellant S" (as defined by Example 20) 99.376
  • Example 35 Anhydrous cyanocobalamin, crystalline, micronized 0.039 Span 85 0.25 Propellant S (as defined by Example 20) 99.711
  • Example 36 Chlorotetracycline hydrochloride, crystalline, mi-
  • Example 37 Adrenochrome, crystalline, micronized 1.785 Span 85 Propellant S" (as defined by Example 20) 97.215
  • a self-propelling, powder dispensing composition capable of producing a useful substance in aerosol form comprising between about 0.01% and 20% by weight of a finely-divided powder of a particle size less than about microns suspended in a liquefied propellant having a vapor pressure of at least about 13 lbs.
  • said composition shall contain not more than about 300 parts per million of moisture.
  • a self-propelling, powder dispensing composition as defined by claim 8 wherein the finely-divided powder comprises isoproterenol hydrochloride.
  • a self-propelling, powder dispensing pharmaceutical composition capable of providing a medicament in aerosol form suitable for inhalation therapy, comprising a liquefied non-toxic propellant having a vapor pressure of at least about 13 lbs. per square inch gauge at 70 F., between about 0.01% and 20% by weight of a finelydivided therapeutically active powdered medicament of substantially uniform particle size of less than about 100 microns suspended in said propellant, and between about 0.1% and 20% by weight of a liquid non-toxic non-ionic surface active agent having a hydrophile-lipophile balance ratio of less than about 10 and being soluble in said liquefied propellant; said finely-divided powder being substantially insoluble in the mixture of propellant and surface active agent; and when said finely-divided powder is watersoluble, said composition shall contain not more than about 300 parts per million of moisture.
  • a self-propelling, powder dispensing composition capable of producing a useful substance in aerosol form comprising a composition as defined in claim 1, wherein the specific gravity of the finely divided powder is at least as great as that of the liquefied propellant.
  • a self-propelling, powder dispensing composition capable of producing a useful substance in aerosol form comprising a composition as defined by claim 1 having "11 units by weight of a useful substance of specific gravity as a finely-divided powder and aunits by weight of an auxiliary solid substance of specific gravity p in powdered form suspended in a liquid of specific gravity pp wherein the minimum value of is expressed as follows:
  • a self-propelling powder dispensing composition capable of producing a useful substance in aerosol form according to claim 22', wherein the auxiliary solid is sodium sulfate.
  • a self-propelling, powder dispensing composition capable of producing a useful substance in aerosol form according to claim 22, wherein the auxiliary solid is calcium chloride.
  • a self-propelling, powder dispensing composition capable of producing a useful substance in aerosol form according to claim 22, wherein the auxiliary solid is lactose.
  • a self-propelling, powder dispensing composition capable of producing a useful substance in aerosol form according to claim 22, wherein the auxiliary solid is sucrose.
  • a package comprising a pressure-tight container having a valve-controlled opening and containing alpharmaceutical composition capable of providing a measured dose of medicament in aerosol form suitable for inhalation therapy, comprising a composition as defined by claim 20 31.
  • pages 324, 328 read pages 324 through 328 Signed and sealed this 24th day of April 1962.
  • pages 324, 328 read pages 324 through 328 Signed and sealed this 24th day of April 1962.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Materials Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
US706908A 1957-01-31 1958-01-03 Self-propelling powder dispensing compositions Expired - Lifetime US3014844A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BE556587D BE556587A (en(2012)) 1957-01-31 1957-04-30
US706908A US3014844A (en) 1957-01-31 1958-01-03 Self-propelling powder dispensing compositions
GB2644/58A GB837465A (en) 1957-01-31 1958-01-27 Self-propelling, powder-dispensing compositions
DER22567A DE1178975B (de) 1957-01-31 1958-01-27 Verfahren zum Herstellen eines Inhalationsmittels
FR756970A FR1228811A (fr) 1957-01-31 1958-01-29 Composition auto-propulsante pour la distribution de poudre
NL224547D NL224547A (en(2012)) 1957-01-31 1958-01-31
NL224547A NL106832C (en(2012)) 1957-01-31 1958-01-31

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63735357A 1957-01-31 1957-01-31
US68001657A 1957-08-23 1957-08-23
US706908A US3014844A (en) 1957-01-31 1958-01-03 Self-propelling powder dispensing compositions

Publications (1)

Publication Number Publication Date
US3014844A true US3014844A (en) 1961-12-26

Family

ID=22180422

Family Applications (1)

Application Number Title Priority Date Filing Date
US706908A Expired - Lifetime US3014844A (en) 1957-01-31 1958-01-03 Self-propelling powder dispensing compositions

Country Status (6)

Country Link
US (1) US3014844A (en(2012))
BE (1) BE556587A (en(2012))
DE (1) DE1178975B (en(2012))
FR (1) FR1228811A (en(2012))
GB (1) GB837465A (en(2012))
NL (2) NL224547A (en(2012))

Cited By (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076745A (en) * 1958-11-17 1963-02-05 Poultry Service And Res Corp Antibiotic method for promoting poultry growth
US3079299A (en) * 1959-11-16 1963-02-26 Gen Aerosol Corp Self-propelling medicinal ointment composition containing polyethylene and method ofapplication
US3088874A (en) * 1960-05-23 1963-05-07 Union Carbide Corp Powder aerosol
US3095355A (en) * 1961-10-12 1963-06-25 Revlon Aerosol composition
US3124505A (en) * 1964-03-10 Aerosol concentrates containing a sta-
US3135658A (en) * 1961-10-10 1964-06-02 Merck & Co Inc Non-aqueous oleaginous aerosol foam therapy of bovine mastitis
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
US3155574A (en) * 1962-05-24 1964-11-03 Revlon Aerosol composition
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
US3219533A (en) * 1962-11-29 1965-11-23 Merck & Co Inc Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation
US3260408A (en) * 1964-04-08 1966-07-12 Bell & Howell Co Method and means of dispersing particulate material in a stream of carrier fluid
US3282791A (en) * 1965-08-17 1966-11-01 Merck & Co Inc Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
US3288681A (en) * 1962-05-01 1966-11-29 Lever Brothers Ltd Anhydrous aluminum antiperspirant powder aerosol compositions and methods of preparation
US3304230A (en) * 1963-02-18 1967-02-14 Revlon Liquid aerosol propellant solutions of fatty acid salts of physiologically active amines
US3345295A (en) * 1963-02-13 1967-10-03 Shulton Inc Copper cleaning compositions
US3402665A (en) * 1966-08-15 1968-09-24 Aeroprojects Inc Nonpyrotechnic disseminator
US3446892A (en) * 1963-09-18 1969-05-27 Whitmire Research Lab Inc Immobilizing insects by sudden reduction of body temperature
DE2320111A1 (de) * 1972-04-20 1973-10-31 Allen & Hanburys Ltd Solvatisierte, kristalline, antiinflammatorisch wirkende steroide, verfahren zu deren herstellung und diese materialien enthaltende aerosolformulierungen
US3923971A (en) * 1973-09-13 1975-12-02 Alexandre Seilinger Antiperspirant and deodorant composition containing lamellar substances
US3968203A (en) * 1965-10-01 1976-07-06 Jerome G. Spitzer Aerosol astringent composition
US4010252A (en) * 1974-12-19 1977-03-01 Colgate-Palmolive Company Antimicrobial compositions
US4027007A (en) * 1970-12-09 1977-05-31 Colgate-Palmolive Company Antiperspirants formulated with borax
DE2703119A1 (de) * 1976-01-30 1977-08-04 Fisons Ltd Dinatriumcromoglycat mit weniger als 5 % wasser und dieses umfassende pharmazeutische praeparate
DE2831419A1 (de) * 1977-07-19 1979-02-01 Fisons Ltd Dispersion oder suspension aus lecithin oder einem sorbitan- oder sorbit-ester in treibmittel 12
US4147766A (en) * 1976-06-09 1979-04-03 Armour Pharmaceutical Company Macrospherical particles of anti-perspirants
US4192766A (en) * 1975-04-25 1980-03-11 United Chemical Corporation Composition for decreasing water resistance to movement
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
EP0047122A3 (en) * 1980-08-28 1983-01-26 Eli Lilly And Company Intranasal formulation
US4411883A (en) * 1973-02-05 1983-10-25 Colgate-Palmolive Company Antiperspirant
US4450151A (en) * 1978-08-21 1984-05-22 Toyo Aerosol Industry Co., Ltd. Powder aerosol composition
JPS60252410A (ja) * 1984-04-25 1985-12-13 イーライ・リリー・アンド・カンパニー 徐放性経鼻用製剤およびその使用方法
US4605552A (en) * 1983-07-20 1986-08-12 Warner-Lambert Company Calcium-antagonist compositions intended for inhalation and process for their manufacture
EP0160501A3 (en) * 1984-04-25 1986-12-30 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5348730A (en) * 1989-09-20 1994-09-20 Minnesota Mining And Manufacturing Company Method for preparing medicinal aerosol formulation containing coated medicament
US5368842A (en) * 1992-10-29 1994-11-29 The Gillette Company High efficacy aerosol antiperspirant composition
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5674472A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Canisters containing aerosol formulations containing P134a and fluticasone propionate
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5756071A (en) * 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5776432A (en) * 1990-10-18 1998-07-07 Minnesota Mining And Manufacturing Company Beclomethasone solution aerosol formulations
US5817293A (en) * 1991-12-12 1998-10-06 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5922306A (en) * 1991-12-12 1999-07-13 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5952008A (en) * 1993-06-24 1999-09-14 Ab Astra Processes for preparing compositions for inhalation
US6004574A (en) * 1994-12-22 1999-12-21 Astra Aktiebolag Powder formulations containing melezitose as a diluent
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
WO1999065460A3 (en) * 1998-06-19 2000-04-27 Baker Norton Pharma Pressurized metered dose inhalers and pharmaceutical aerosol formulations comprising a beta-agonist
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6306440B1 (en) 1993-06-24 2001-10-23 Astrazeneca Ab Therapeutic preparation for inhalation
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20020010318A1 (en) * 1997-10-03 2002-01-24 Amgen, Inc. Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6436902B1 (en) 1994-12-22 2002-08-20 Astrazeneca Ab Therapeutic preparations for inhalation
US6461591B1 (en) 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
US6475467B1 (en) 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6585958B1 (en) 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
US6610653B1 (en) 1994-06-23 2003-08-26 Astrazeneca Ab Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US20030211972A1 (en) * 1993-06-24 2003-11-13 Astrazeneca Ab, A Sweden Corporation Systemic administration of a therapeutic preparation
US6743413B1 (en) 1991-12-18 2004-06-01 3M Company Suspension aerosol formulations
US20040171550A1 (en) * 1993-06-24 2004-09-02 Astrazeneca Ab, A Swedish Corporation Compositions for inhalation
US20050031548A1 (en) * 1990-02-03 2005-02-10 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
US6932962B1 (en) 1994-12-22 2005-08-23 Astrazeneca Ab Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US20080287451A1 (en) * 2007-02-11 2008-11-20 Cook Robert O Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US7566445B1 (en) 1996-08-01 2009-07-28 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US20090191134A1 (en) * 2006-06-12 2009-07-30 Medispray Laboratoriespvt. Ltd. Stable aerosol pharmaceutical formulations
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US20090297457A1 (en) * 2004-10-12 2009-12-03 Generics [Uk] Limited Preparation Of Suspension Aerosol Formulations
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8080236B2 (en) 2002-04-17 2011-12-20 Nektar Therapeutics Uk, Ltd Particulate materials
WO2012106382A1 (en) 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US8246934B2 (en) 1997-09-29 2012-08-21 Novartis Ag Respiratory dispersion for metered dose inhalers comprising perforated microstructures
US8357696B2 (en) 2005-05-18 2013-01-22 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
EP2594272A2 (en) 2005-05-18 2013-05-22 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
US8815838B2 (en) 2008-10-07 2014-08-26 David C. Griffith Aerosol fluoroquinolone formulations for improved pharmacokinetics
US9700564B2 (en) 2009-09-04 2017-07-11 Horizon Orphan Llc Use of aerosolized levofloxacin for treating cystic fibrosis
US10028966B2 (en) 2014-01-10 2018-07-24 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof
US11633556B2 (en) 2017-09-22 2023-04-25 Imperial Tobacco Limited Aerosolization using two aerosol generators

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1170909B (de) * 1961-02-17 1964-05-27 Specialties Dev Corp Selbsttreibendes Gemisch
DE2804931A1 (de) * 1978-02-06 1979-08-16 Fresenius Chem Pharm Ind Metallsulfadiazine in feinteiliger form
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
EP0460064A4 (en) * 1989-02-23 1992-04-01 Rorer International (Holdings) Inc. Therapeutic aerosol formulations
HU205249B (en) * 1990-11-09 1992-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing suspensive aerosole composition
RU2054180C1 (ru) * 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
GB0614621D0 (en) 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
GB0620700D0 (en) 2006-10-19 2006-11-29 3M Innovative Properties Co Metered dose valves and dispensers
GB201118188D0 (en) 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
GB201210580D0 (en) 2012-06-14 2012-08-01 3M Innovative Properties Co Metered dose dispensing valve
GB201221063D0 (en) 2012-11-23 2013-01-09 3M Innovative Properties Co Metered dose dispensing valve

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594296A (en) * 1948-06-24 1952-04-29 Aerosol Corp Lobeline aerosol dilating medicament
US2728495A (en) * 1951-04-19 1955-12-27 Little Inc A Liquid dispensing device and composition therefor
US2782975A (en) * 1955-04-20 1957-02-26 American Cyanamid Co Sprayable amorphous antibiotic composition, pressurized container with same, and method of preparing
US2959325A (en) * 1954-04-29 1960-11-08 Risdon Mfg Co Method and apparatus for dispensing dry powders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2440915A (en) * 1946-01-03 1948-05-04 Roberts Mfg Co Process for producing aerosols
US2524590A (en) * 1946-04-22 1950-10-03 Carsten F Boe Emulsion containing a liquefied propellant gas under pressure and method of spraying same
GB764862A (en) * 1953-02-16 1957-01-02 Midland Silicones Ltd An article for dispensing organosilicon compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594296A (en) * 1948-06-24 1952-04-29 Aerosol Corp Lobeline aerosol dilating medicament
US2728495A (en) * 1951-04-19 1955-12-27 Little Inc A Liquid dispensing device and composition therefor
US2959325A (en) * 1954-04-29 1960-11-08 Risdon Mfg Co Method and apparatus for dispensing dry powders
US2782975A (en) * 1955-04-20 1957-02-26 American Cyanamid Co Sprayable amorphous antibiotic composition, pressurized container with same, and method of preparing

Cited By (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3124505A (en) * 1964-03-10 Aerosol concentrates containing a sta-
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
US3076745A (en) * 1958-11-17 1963-02-05 Poultry Service And Res Corp Antibiotic method for promoting poultry growth
US3079299A (en) * 1959-11-16 1963-02-26 Gen Aerosol Corp Self-propelling medicinal ointment composition containing polyethylene and method ofapplication
US3088874A (en) * 1960-05-23 1963-05-07 Union Carbide Corp Powder aerosol
US3135658A (en) * 1961-10-10 1964-06-02 Merck & Co Inc Non-aqueous oleaginous aerosol foam therapy of bovine mastitis
US3095355A (en) * 1961-10-12 1963-06-25 Revlon Aerosol composition
US3288681A (en) * 1962-05-01 1966-11-29 Lever Brothers Ltd Anhydrous aluminum antiperspirant powder aerosol compositions and methods of preparation
US3155574A (en) * 1962-05-24 1964-11-03 Revlon Aerosol composition
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
US3219533A (en) * 1962-11-29 1965-11-23 Merck & Co Inc Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation
US3345295A (en) * 1963-02-13 1967-10-03 Shulton Inc Copper cleaning compositions
US3304230A (en) * 1963-02-18 1967-02-14 Revlon Liquid aerosol propellant solutions of fatty acid salts of physiologically active amines
US3446892A (en) * 1963-09-18 1969-05-27 Whitmire Research Lab Inc Immobilizing insects by sudden reduction of body temperature
US3260408A (en) * 1964-04-08 1966-07-12 Bell & Howell Co Method and means of dispersing particulate material in a stream of carrier fluid
US3282791A (en) * 1965-08-17 1966-11-01 Merck & Co Inc Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
US3968203A (en) * 1965-10-01 1976-07-06 Jerome G. Spitzer Aerosol astringent composition
US3402665A (en) * 1966-08-15 1968-09-24 Aeroprojects Inc Nonpyrotechnic disseminator
US4027007A (en) * 1970-12-09 1977-05-31 Colgate-Palmolive Company Antiperspirants formulated with borax
DE2320111A1 (de) * 1972-04-20 1973-10-31 Allen & Hanburys Ltd Solvatisierte, kristalline, antiinflammatorisch wirkende steroide, verfahren zu deren herstellung und diese materialien enthaltende aerosolformulierungen
US4411883A (en) * 1973-02-05 1983-10-25 Colgate-Palmolive Company Antiperspirant
US3923971A (en) * 1973-09-13 1975-12-02 Alexandre Seilinger Antiperspirant and deodorant composition containing lamellar substances
US4010252A (en) * 1974-12-19 1977-03-01 Colgate-Palmolive Company Antimicrobial compositions
US4192766A (en) * 1975-04-25 1980-03-11 United Chemical Corporation Composition for decreasing water resistance to movement
DE2703119A1 (de) * 1976-01-30 1977-08-04 Fisons Ltd Dinatriumcromoglycat mit weniger als 5 % wasser und dieses umfassende pharmazeutische praeparate
US4147766A (en) * 1976-06-09 1979-04-03 Armour Pharmaceutical Company Macrospherical particles of anti-perspirants
DE2831419A1 (de) * 1977-07-19 1979-02-01 Fisons Ltd Dispersion oder suspension aus lecithin oder einem sorbitan- oder sorbit-ester in treibmittel 12
FR2397833A1 (fr) * 1977-07-19 1979-02-16 Fisons Ltd Compositions en emballage sous pression
US4450151A (en) * 1978-08-21 1984-05-22 Toyo Aerosol Industry Co., Ltd. Powder aerosol composition
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
EP0047122A3 (en) * 1980-08-28 1983-01-26 Eli Lilly And Company Intranasal formulation
US4605552A (en) * 1983-07-20 1986-08-12 Warner-Lambert Company Calcium-antagonist compositions intended for inhalation and process for their manufacture
JPS60252410A (ja) * 1984-04-25 1985-12-13 イーライ・リリー・アンド・カンパニー 徐放性経鼻用製剤およびその使用方法
EP0160501A3 (en) * 1984-04-25 1986-12-30 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
US5681545A (en) * 1988-12-06 1997-10-28 Riker Laboratories, Inc. Medicinal aerosol formulations
US5683677A (en) * 1988-12-06 1997-11-04 Riker Laboratories, Inc. Medicinal aerosol formulations
US5720940A (en) * 1988-12-06 1998-02-24 Riker Laboratories, Inc. Medicinal aerosol formulations
US5695743A (en) * 1988-12-06 1997-12-09 Riker Laboratories, Inc. Medicinal aerosol formulations
US5605674A (en) * 1988-12-06 1997-02-25 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US6352684B1 (en) 1988-12-06 2002-03-05 Riker Laboratories Inc. CRC-free medicinal aerosol formulations of 1,1,1,2-tetrafluoroethane (134A) with polar adjuvant
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5674473A (en) * 1988-12-06 1997-10-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5348730A (en) * 1989-09-20 1994-09-20 Minnesota Mining And Manufacturing Company Method for preparing medicinal aerosol formulation containing coated medicament
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US20050031548A1 (en) * 1990-02-03 2005-02-10 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
US7160538B2 (en) 1990-02-03 2007-01-09 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
US20090104127A1 (en) * 1990-02-03 2009-04-23 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
US20110014134A1 (en) * 1990-02-03 2011-01-20 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
US6346232B1 (en) 1990-10-18 2002-02-12 3M Innovative Properties Company Method of forming conductive lines
US5776432A (en) * 1990-10-18 1998-07-07 Minnesota Mining And Manufacturing Company Beclomethasone solution aerosol formulations
US20030198600A1 (en) * 1991-12-12 2003-10-23 Glaxo Group Limited Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
US20030143163A1 (en) * 1991-12-12 2003-07-31 Glaxo Group Limited Medicaments
US20090188491A1 (en) * 1991-12-12 2009-07-30 Glaxo Group Limited Medicaments
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5817293A (en) * 1991-12-12 1998-10-06 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US7498020B2 (en) 1991-12-12 2009-03-03 Glaxo Group Limited Medicaments
US5922306A (en) * 1991-12-12 1999-07-13 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US20050232873A1 (en) * 1991-12-12 2005-10-20 Glaxo Group Limited Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
US20050207991A1 (en) * 1991-12-12 2005-09-22 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US6919069B2 (en) 1991-12-12 2005-07-19 Glaxo Group Limited Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
US6200549B1 (en) 1991-12-12 2001-03-13 Glaxo Group Limited Aerosol formulation containing P134a and particulate medicament
US6221339B1 (en) 1991-12-12 2001-04-24 Glaxo Group Limited Medicaments
US6238647B1 (en) 1991-12-12 2001-05-29 Glaxo Group Limited Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane
US6251368B1 (en) 1991-12-12 2001-06-26 Glaxo Group Limited Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant
US6893628B2 (en) 1991-12-12 2005-05-17 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US6303103B1 (en) 1991-12-12 2001-10-16 Glaxo Group Limited Aerosols containing salmeterol xinafoate and an anticholinergic medicament
US20050089477A1 (en) * 1991-12-12 2005-04-28 Glaxo Group Limited Medicaments
US6306369B1 (en) 1991-12-12 2001-10-23 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5674472A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Canisters containing aerosol formulations containing P134a and fluticasone propionate
US6333023B1 (en) 1991-12-12 2001-12-25 Glaxo Group Limited Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5676929A (en) * 1991-12-12 1997-10-14 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US20030165437A1 (en) * 1991-12-12 2003-09-04 Glaxo Group Limited Aerosos formulations containing P134a and particulate medicament
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US6743413B1 (en) 1991-12-18 2004-06-01 3M Company Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US20040197273A1 (en) * 1991-12-18 2004-10-07 3M Company Suspension aerosol formulations
US5756071A (en) * 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
US5368842A (en) * 1992-10-29 1994-11-29 The Gillette Company High efficacy aerosol antiperspirant composition
US6846801B1 (en) 1993-06-24 2005-01-25 Astrazeneca Ab Systemic administration of a therapeutic preparation
US20040171550A1 (en) * 1993-06-24 2004-09-02 Astrazeneca Ab, A Swedish Corporation Compositions for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5952008A (en) * 1993-06-24 1999-09-14 Ab Astra Processes for preparing compositions for inhalation
US6306440B1 (en) 1993-06-24 2001-10-23 Astrazeneca Ab Therapeutic preparation for inhalation
US20030211972A1 (en) * 1993-06-24 2003-11-13 Astrazeneca Ab, A Sweden Corporation Systemic administration of a therapeutic preparation
US20030216541A1 (en) * 1993-06-24 2003-11-20 Astrazeneca Ab, A Swedish Corporation Systemic administration of a therapeutic preparation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6610653B1 (en) 1994-06-23 2003-08-26 Astrazeneca Ab Therapeutic preparation for inhalation
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6004574A (en) * 1994-12-22 1999-12-21 Astra Aktiebolag Powder formulations containing melezitose as a diluent
US20030064928A1 (en) * 1994-12-22 2003-04-03 Astra Aktiebolag, A Sweden Corporation Therapeutic preparations for inhalation
US6436902B1 (en) 1994-12-22 2002-08-20 Astrazeneca Ab Therapeutic preparations for inhalation
US6932962B1 (en) 1994-12-22 2005-08-23 Astrazeneca Ab Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US7566445B1 (en) 1996-08-01 2009-07-28 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US20090246148A1 (en) * 1996-08-01 2009-10-01 Norton Healthcare Ltd Medicinal aerosols and methods of delivery thereof
US8834849B2 (en) 1996-08-01 2014-09-16 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US9650203B2 (en) 1996-08-01 2017-05-16 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US6461591B1 (en) 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
US7628978B2 (en) 1997-09-29 2009-12-08 Novartis Pharma Ag Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US8080263B2 (en) 1997-09-29 2011-12-20 Novartis Ag Dispersion for pulmonary delivery of a bioactive agent
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US8168223B1 (en) 1997-09-29 2012-05-01 Novartis Pharma Ag Engineered particles and methods of use
US7205343B2 (en) 1997-09-29 2007-04-17 Dellamary Luis A Stabilized bioactive preparations and method of use
US7306787B2 (en) 1997-09-29 2007-12-11 Nektar Therapeutics Engineered particles and methods of use
US20050207986A1 (en) * 1997-09-29 2005-09-22 Schutt Ernest G Stabilized preparations for use in nebulizers
US7393544B2 (en) 1997-09-29 2008-07-01 Nektar Therapeutics Dispersion for pulmonary delivery of a bioactive agent
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US8246934B2 (en) 1997-09-29 2012-08-21 Novartis Ag Respiratory dispersion for metered dose inhalers comprising perforated microstructures
US6638495B2 (en) 1997-09-29 2003-10-28 Nektar Therapeutics Stabilized preparation for use in metered dose inhalers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20020010318A1 (en) * 1997-10-03 2002-01-24 Amgen, Inc. Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
WO1999065460A3 (en) * 1998-06-19 2000-04-27 Baker Norton Pharma Pressurized metered dose inhalers and pharmaceutical aerosol formulations comprising a beta-agonist
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
EP1306082A1 (en) * 1998-06-19 2003-05-02 Baker Norton Pharmaceuticals, Inc. Pressurized metered dose inhalers and pharmaceutical aerosol formulations
US6585958B1 (en) 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
US6475467B1 (en) 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US8349294B2 (en) 2000-05-10 2013-01-08 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US8709484B2 (en) 2000-05-10 2014-04-29 Novartis Ag Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US8715623B2 (en) 2001-12-19 2014-05-06 Novartis Ag Pulmonary delivery of aminoglycoside
US8470301B2 (en) 2002-04-17 2013-06-25 Nektar Therapeutics Particulate materials
US8828359B2 (en) 2002-04-17 2014-09-09 Nektar Therapeutics Particulate materials
US9616060B2 (en) 2002-04-17 2017-04-11 Nektar Therapeutics Particulate materials
US8080236B2 (en) 2002-04-17 2011-12-20 Nektar Therapeutics Uk, Ltd Particulate materials
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US10251881B2 (en) 2002-04-17 2019-04-09 Nektar Therapeutics Particulate materials
US9808423B2 (en) 2004-10-12 2017-11-07 Generics [Uk] Limited Preparation of suspension aerosol formulations
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US20090297457A1 (en) * 2004-10-12 2009-12-03 Generics [Uk] Limited Preparation Of Suspension Aerosol Formulations
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US10987357B2 (en) 2005-05-18 2021-04-27 Horizon Orphan, LLC Aerosolized fluoroquinolones and uses thereof
EP2594272A2 (en) 2005-05-18 2013-05-22 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8357696B2 (en) 2005-05-18 2013-01-22 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US20090191134A1 (en) * 2006-06-12 2009-07-30 Medispray Laboratoriespvt. Ltd. Stable aerosol pharmaceutical formulations
US7994197B2 (en) 2007-02-11 2011-08-09 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8119639B2 (en) 2007-02-11 2012-02-21 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20080287451A1 (en) * 2007-02-11 2008-11-20 Cook Robert O Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US10172853B2 (en) 2007-02-11 2019-01-08 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
US9717738B2 (en) 2008-10-07 2017-08-01 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
US11020481B2 (en) 2008-10-07 2021-06-01 Horizon Orphan Llc Topical use of levofloxacin for reducing lung inflammation
US10149854B2 (en) 2008-10-07 2018-12-11 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
US8815838B2 (en) 2008-10-07 2014-08-26 David C. Griffith Aerosol fluoroquinolone formulations for improved pharmacokinetics
US9326936B2 (en) 2008-10-07 2016-05-03 Raptor Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
US10722519B2 (en) 2008-10-07 2020-07-28 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
US9700564B2 (en) 2009-09-04 2017-07-11 Horizon Orphan Llc Use of aerosolized levofloxacin for treating cystic fibrosis
US10231975B2 (en) 2009-09-04 2019-03-19 Horizon Orphan Llc Use of aerosolized levofloxacin for treating cystic fibrosis
US10792289B2 (en) 2009-09-04 2020-10-06 Horizon Orphan Llc Use of aerosolized levofloxacin for treating cystic fibrosis
WO2012106382A1 (en) 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP4059499A1 (en) 2011-01-31 2022-09-21 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US10028966B2 (en) 2014-01-10 2018-07-24 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP4491180A1 (en) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US11633556B2 (en) 2017-09-22 2023-04-25 Imperial Tobacco Limited Aerosolization using two aerosol generators
US12029846B2 (en) 2017-09-22 2024-07-09 Imperial Tobacco Limited Aerosolization using two aerosol generators
US12059525B2 (en) 2017-09-22 2024-08-13 Nerudia Limited Substitute smoking device comprising multiple aerosols and passive aerosol generation
US12337105B2 (en) 2017-09-22 2025-06-24 Imperial Tobacco Limited Aerosolization using two aerosol generators
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof

Also Published As

Publication number Publication date
BE556587A (en(2012)) 1957-04-11
GB837465A (en) 1960-06-15
DE1178975B (de) 1964-10-01
NL224547A (en(2012))
NL106832C (en(2012)) 1963-12-16
FR1228811A (fr) 1960-09-02

Similar Documents

Publication Publication Date Title
US3014844A (en) Self-propelling powder dispensing compositions
US5334374A (en) Pharmaceutical compositions containing pentamidine
US5204113A (en) Pharmaceutical compositions containing pentamidine
US4352789A (en) Aerosol compositions containing finely divided solid materials
JP4570251B2 (ja) 医薬用エーロゾル製剤
AU718967B2 (en) Medical aerosol formulations
RU2294737C2 (ru) Медицинские аэрозольные составы
CA2352483C (en) Pharmaceutical aerosol composition containing hfa 227 and hfa 134a
US5292499A (en) Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
RU2129424C1 (ru) Аэрозольная фармацевтическая композиция, способ лечения респираторных заболеваний
AU749697B2 (en) Medicinal aerosol formulations
US3169095A (en) Self-propelling powder-dispensing compositions
US20070253913A1 (en) Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
AU2002211311B2 (en) Medicinal aerosol formulations
SK140593A3 (en) Non-chlorofluorocarbon aerosol formulations
JPH10510521A (ja) エアゾール処方物用噴射剤混合物
HUP0001339A2 (hu) Aeroszol gyógyszerkészítmény
WO1990011754A1 (en) Aerosolized azole antifungals
US6129905A (en) Aerosol formulations containing a sugar as a dispersant
CA1083963A (en) Use of flunisolide to treat respiratory diseases
AU774250B2 (en) Pharmaceutical aerosol composition
SE178687C1 (en(2012))
ITMI982559A1 (it) "inalatori dosati per pressurizzatori"